1331944-00-3

Basic information

• Product Name: 2-(4-bromo-3-fluorophenyl)ethan-1-ol
• Synonyms: 2-(4-bromo-3-fluorophenyl)ethan-1-ol
• CAS NO: 1331944-00-3
• Molecular Weight: 219.053
• Mol File: 1331944-00-3.mol

Chemical Properties

• CAS DataBase Reference: 2-(4-bromo-3-fluorophenyl)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-bromo-3-fluorophenyl)ethan-1-ol(1331944-00-3)
• EPA Substance Registry System: 2-(4-bromo-3-fluorophenyl)ethan-1-ol(1331944-00-3)

Safety Data

• Hazardous Substances Data: 1331944-00-3(Hazardous Substances Data)

Usage

Organic compound

Contains a phenyl ring
The compound has a six-membered carbon ring with delocalized electrons, which is characteristic of aromatic compounds.

Substituents

4-bromo and 3-fluoro

The phenyl ring has two substituents

a bromine atom at the 4-position and a fluorine atom at the 3-position.

Alcohol functional group

Ethan-1-ol
The compound contains a hydroxyl (-OH) group, which is characteristic of alcohols.

Hydroxyl group location

First carbon of the ethyl chain
The hydroxyl group is attached to the first carbon atom in the two-carbon ethyl chain.

Potential applications

Organic synthesis, pharmaceuticals, material science
Due to its unique structure and potential reactivity, the compound may be useful in various fields, such as creating new organic compounds, developing drugs, or designing new materials.

Precautions

Potential hazards and risks
The compound should be handled and used with care, as it may pose health or environmental risks.

Upstream product

• 942282-41-9 methyl 2-(4-bromo-3-fluorophenyl)acetate 
• 499983-13-0 2-( 4-bromo-3-fluorophenyl)acetonitrile 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 
• 942282-40-8 2-(4-bromo-3-fluorophenyl)acetic acid 

Relevant articles and documents

Synthesis and inhibitory studies of phosphonic acid analogues of homophenylalanine and phenylalanine towards alanyl aminopeptidases

A library of novel phosphonic acid analogues of homophenylalanine and phenylalanine, containing fluorine and bromine atoms in the phenyl ring, have been synthesized. Their inhibitory properties against two important alanine aminopeptidases, of human (hAPN, CD13) and porcine (pAPN) origin, were evaluated. Enzymatic studies and comparison with literature data indicated the higher inhibitory potential of the homophenylalanine over phenylalanine derivatives towards both enzymes. Their inhibition constants were in the submicromolar range for hAPN and the micromolar range for pAPN, with 1-amino-3-(3-fluorophenyl) propylphosphonic acid (compound 15c) being one of the best low-molecular inhibitors of both enzymes. To the best of our knowledge, P1 homophenylalanine analogues are the most active inhibitors of the APN among phosphonic and phosphinic derivatives described in the literature. Therefore, they constitute interesting building blocks for the further design of chemically more complex inhibitors. Based on molecular modeling simulations and SAR (structure-activity relationship) analysis, the optimal architecture of enzyme-inhibitor complexes for hAPN and pAPN were determined.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS

The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

AZOLE DERIVATIVE

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:

1, 2, 4-TRIAZOLONE DERIVATIVE

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.